Metabolic and Nutritional Complications of Renal Transplantation

Journal of Renal Nutrition

Volumn 17, Issue 1, 2007, Pages 97-102

  Dumler, Francis ^a   Kilates, Cristina ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; KIDNEY TRANSPLANTATION;

DIABETES MELLITUS; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION;

EID: 33845768400     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2006.10.017     Document Type: Article

References (38)

1. US Renal Data System (USRDS). 2005 Annual Data Report Atlas of End-Stage Renal Disease in the United States (2005), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland
2. Kendrick E. Cardiovascular disease and the renal transplant patient. Am J Kidney Dis 38 suppl 16 (2001) S36-S43
3. Andany M.A., and Kasiske B.L. Dyslipidemia and its management after renal transplantation. J Nephrol 14 suppl 4 (2001) S81-S88
4. Berg A.L., and Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int 50 (1996) 538-542
5. Ahsan N., Hricik D., Matas A., et al., Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-A prospective randomized study. Transplantation 68 (1999) 1865-1874
6. Vanrenterghem Y., Lebranchu Y., Hene R., et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 70 (2000) 1352-1359
7. Artz M.A., Boots J.M.M., Ligtenberg G., et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 14 (2003) 1880-1888
8. Groth C.G., Backman L., Morales J.M., et al., Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 67 (1999) 1036-1042
9. Grundy S.M., Cleeman J.I., Merz C.N., et al., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
10. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation kidney disease outcomes quality initiative. Am J Transplant 4 suppl 7 (2004) 13-53
11. Buchanan C., Smith L., Corbett J., et al. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 6 (2006) 770-774
12. Holdaas H., Fellström B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am J Transplant 5 (2005) 2929-2936
13. Holdaas H., Fellström B., Jardine A.G., et al. Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation. Nephrol Dial Transplant 20 (2005) 974-980
14. Gupta B.K., Glicklich D., and Tellis V.A. Magnesium repletion therapy improved lipid metabolism in hypomagnesemic renal transplant recipients: A pilot study. Transplantation 67 (1999) 1485-1487
15. Holdaas H., Fellström B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 361 (2003) 2024-2031
16. Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 International Consensus Guidelines. Transplantation 75 suppl 10 (2003) SS3-SS24
17. Kasiske B.L., Snyder J.J., Gilbertson D., et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3 (2003) 178-185
18. Cosio F.G., Pesavento T.E., Osei K., et al. Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 59 (2001) 732-737
19. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3 (2003) 590-598
20. Friedman A.N., Miskulin D.C., Rosenberg I.H., et al. Demographics and trends in overweight and obesity in patients at time of kidney transplantation. Am J Kidney Dis 41 (2003) 480-487
21. Gurwitz J.H., Bohn R.L., Glynn R.J., et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 154 (1994) 97-101
22. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 64 (1997) 979-983
23. Hjelmesaeth J., Hartmann A., Kofstad J., et al. Tapering off prednisolone and cyclosporin the first year after renal transplantation: The effect on glucose tolerance. Nephrol Dial Transplant 16 (2001) 829-835
24. Midtvedt K., Hjelmesaeth J., Hartmann A., et al. Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 15 (2004) 3233
25. Maes B.D., Kuypers D., Messiaen T., et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: Analysis of incidence and risk factors. Transplantation 72 (2001) 1655-1661
26. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69 (2000) 834-841
27. Gonwa T., Mendez R., Yang H.C., et al. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months. Transplantation 75 (2003) 1213-1220
28. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus/sirolimus vs tacrolimus/mycophenolate mofetil vs cyclosporine (Neoral)/sirolimus in renal transplantation. II. Survival, function and protocol compliance at 1 year. Transplantation 74 (2004) 1703-1709
29. Miles A.M., Sumrani N., Horowitz R., et al. Diabetes mellitus after renal transplantation: As deleterious as non-transplant-associated diabetes?. Transplantation 65 (1998) 380-384
30. Owda A.K., Abdallah A.H., Haleem A., et al. De novo diabetes mellitus in kidney allografts: Nodular sclerosis and diffuse glomerulosclerosis leading to graft failure. Nephrol Dial Transplant 14 (1999) 2004-2007
31. Gillespie E.L., White C.M., Kardas M., et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28 (2005) 2261-2266
32. Prasad G.V., Kim S.J., Huang M., et al. Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). Am J Transplant 4 (2004) 1897-1903
33. Vasan R.S., Beiser A., D'Agostino R.B., et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 289 (2003) 1251-1257
34. Bostom A.G., Shemin D., Verhoef P., et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arteroscler Thomb Vasc Biol 17 (1997) 2554-2558
35. Ducloux D., Motte G., Challier B., et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study. J Am Soc Nephrol 11 (2000) 134-137
36. Ducloux D., Kazory A., and Chalopin J.M. Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 66 (2004) 441-447
37. Winkelmayer W.C., Kramar R., Curhan G.C., et al. Fasting plasma total homocysteine levels and morality and allograft loss in kidney transplant recipients: A prospective study. J Am Soc Nephrol 16 (2005) 255-260
38. Diaz J.M., Sainz Z., Vich I., et al. Determining factors of the response to hyperhomocysteinemia treatment in renal transplant patients. Transplant Proc 37 (2005) 3785-3787